Valuation: Clene Inc.

Market Cap 80.12M 70.08M 64.64M 59.7M 113M 7.64B 115M 772M 303M 3.76B 301M 294M 12.94B P/E 2026 *
-3.51x
P/E 2027 * -4.26x
Enterprise Value 66.72M 58.36M 53.83M 49.72M 94.34M 6.36B 95.92M 643M 253M 3.13B 251M 245M 10.78B EV / Sales 2026 *
322x
EV / Sales 2027 * 2.48x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week+2.79%
Current month+1.87%
1 month+13.38%
3 months+2.62%
6 months-1.95%
Current year+6.81%
1 week 5.83
Extreme 5.83
6.38
1 month 5.5
Extreme 5.5
6.46
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
17
5 years 2.28
Extreme 2.2801
356.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 31/03/2013
Chief Tech/Sci/R&D Officer 67 31/12/2012
Director of Finance/CFO 57 31/01/2022
Director TitleAgeSince
Chairman 65 31/10/2015
Director/Board Member 53 31/08/2019
Director/Board Member 49 30/11/2020
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Chief Financial Officer

15,000 0.1174%
06-10Free

Chief Executive Officer

65,000 0.5087%
06-10Free

Founder

45,000 0.3522%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+2.79%+74.65%-61.25% 80.12M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.88B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.36B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.57%+0.03%+54.32%+186.22% 24.13B
Weighted average by Cap. -0.91%-1.46%+51.27%+176.17%

Financials

2026 *2027 *
Net sales 207K 181K 167K 155K 293K 19.78M 298K 2M 785K 9.74M 779K 762K 33.5M 23.64M 20.68M 19.08M 17.62M 33.43M 2.26B 33.99M 228M 89.51M 1.11B 88.78M 86.85M 3.82B
Net income -25.09M -21.95M -20.25M -18.7M -35.48M -2.39B -36.08M -242M -94.99M -1.18B -94.22M -92.17M -4.05B -27.55M -24.1M -22.23M -20.53M -38.95M -2.63B -39.61M -266M -104M -1.29B -103M -101M -4.45B
Net Debt -13.4M -11.72M -10.81M -9.99M -18.95M -1.28B -19.27M -129M -50.73M -630M -50.31M -49.22M -2.16B -21.4M -18.72M -17.27M -15.95M -30.26M -2.04B -30.77M -206M -81.01M -1.01B -80.35M -78.6M -3.46B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
10/07/26 US$6.270 +0.32% 33,705
09/07/26 US$6.250 +2.80% 50,244
08/07/26 US$6.080 -0.65% 41,043
07/07/26 US$6.120 +1.83% 71,775
06/07/26 US$6.010 -1.48% 40,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.270USD
Average target price
32.20USD
Spread / Average Target
+413.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock